SJScott K. Johnson

Scott K. Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Scott K. Johnson has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety of an adjuvanted thermostable dry powder live attenuated influenza vaccine in ferrets

    by Dawne Rowe Haas, Scott K. Johnson, Cheryl A. Jones, Min-Xuan Wang, Erin A. Miller, Uriel Blas-Machado, Kaori Sakamoto, Nikolai Petrovsky, Victor Bronshtein, Stephen M. Tompkins

    Live Attenuated Influenza Vaccines (LAIV) are attenuated, temperature sensitive, and cold adapted to limit replication to the upper respiratory tract. This modification seeks to prevent clinical disease while effectively eliciting the development of immunity. While LAIVs offer benefits over Inactivated Influenza Vaccines (IIV), thermostability remains a key concern. Using Preservation By Vaporization (PBV), we have established a thermostable LAIV (tLAIV) that is stable at ambient temperature for at least one year and suitable for respiratory delivery in a dry powder form. Using the ferret model, we have demonstrated that tLAIV elicited protective immune responses to subsequent influenza virus infection. Here, we expand on these studies to confirm the safety of tLAIV following intranasal administration. Continuing with the ferret model, we completed a dose-response safety and immunogenicity study of tLAIV formulated both with and without Advax adjuvant and compared the results to those of liquid LAIV controls. Dry-powder vaccination with tLAIV or LAIV did not cause significant temperature elevations, lethargy, weight loss, or other clinical changes. Clinical chemistry and complete blood counts (CBC) remained within established baseline reference ranges. On histopathology, there were no adverse effects seen on the upper or lower respiratory tract 14 days after vaccine delivery. ELISA and hemagglutination inhibition assays (HAI) confirmed seroconversion was induced by all vaccine formulations, with neither dose nor adjuvant improving the magnitude of response. Nasal wash analysis demonstrated that PBV- stabilized tLAIV exhibited comparable infectivity to the same dose of liquid LAIV control. These findings further reinforce the similarity in infectivity, immunogenicity, and safety of intranasal vaccination using PBV-tLAIV, both with and without an adjuvant.

  • Open Access

    Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations

    by Teha Kim, Lynn Bimler, Sydney L. Ronzulli, Amber Y. Song, Scott K. Johnson, Cheryl A. Jones, S. Mark Tompkins, Silke Paust

    Influenza A viruses remain a global health threat, yet no universal antibody therapy exists. Clinical programs have centered on neutralizing mAbs, only to be thwarted by strain specificity and rapid viral escape. We instead engineered three non-neutralizing IgG2a mAbs that target distinct, overlapping epitopes within the conserved N terminus of the M2 ectodomain (M2e). Combined at low dose, this “triple M2e-mAb” confers robust prophylactic and therapeutic protection in mice challenged with diverse human and zoonotic IAV strains, including highly pathogenic variants. Therapeutic efficacy depends on Fc-mediated effector activity via FcγRI, FcγRIII, and FcγRIV, rather than in vitro neutralization. Serial passaging in triple M2e-mAb–treated immunocompetent and immunodeficient hosts failed to generate viral escape mutants. Our findings redefine the influenza-specific antibody therapeutic design and support Fc-optimized, non-neutralizing M2e-mAbs as a broadly effective, mutation-resistant, off-the-shelve therapy with direct relevance to human pandemic preparedness.


  • Open Access

    Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5–based COVID-19 vaccine

    by Dong An, Kun Li, Dawne K. Rowe, Maria Cristina Huertas Diaz, Emily F. Griffin, Ashley C. Beavis, Scott K. Johnson, Ian Padykula, Cheryl A. Jones, Kelsey Briggs, et al.

    Single-dose intranasal COVID-19 vaccine prevents infection and inhibits transmission.